Literature DB >> 11826620

Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

L Rauova1, J Rovensky, Y Shoenfeld.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11826620     DOI: 10.1007/s281-001-8170-y

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


× No keyword cloud information.
  84 in total

Review 1.  Intravenous immune globulin therapy for neurologic diseases.

Authors:  M C Dalakas
Journal:  Ann Intern Med       Date:  1997-05-01       Impact factor: 25.391

Review 2.  Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases.

Authors:  Z Yu; V A Lennon
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

3.  Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report.

Authors:  Y Levy; Y Sherer; P Langevitz; M Lorber; P Rotman; F Fabrizzi; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

4.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

5.  Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG.

Authors:  F Silvestris; O D'Amore; P Cafforio; L Savino; F Dammacco
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

6.  Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin.

Authors:  Y Sherer; Y Levy; P Langevitz; M Lorber; F Fabrizzi; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

7.  Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use.

Authors:  D Caccavo; F Vaccaro; G M Ferri; A Amoroso; L Bonomo
Journal:  J Autoimmun       Date:  1994-08       Impact factor: 7.094

8.  Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

Authors:  J Wada; N Shintani; K Kikutani; T Nakae; T Yamauchi; K Takechi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

9.  Contribution of stabilizing agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell proliferation in vitro.

Authors:  L B Alder; L A Morgan; G P Spickett
Journal:  Scand J Immunol       Date:  1996-12       Impact factor: 3.487

10.  Neutralization of lupus anticoagulant activity by human immunoglobulin "in vitro".

Authors:  P B Said; M E Martinuzzo; L O Carreras
Journal:  Nouv Rev Fr Hematol       Date:  1992
View more
  1 in total

1.  High-dose IgG therapy mitigates bile duct-targeted inflammation and obstruction in a mouse model of biliary atresia.

Authors:  Erika K Fenner; Juri Boguniewicz; Rebecca M Tucker; Ronald J Sokol; Cara L Mack
Journal:  Pediatr Res       Date:  2014-04-11       Impact factor: 3.756

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.